ArticleFrontiers in public health2025
Survival analysis and factors influencing survival time of adult HIV/AIDS patients receiving antiretroviral therapy from 2012 to 2022 in Chongqing, China: a retrospective cohort study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term survival probability and predictors of mortality among adult patients living with HIV initiating combination antiretroviral therapy in Oman: an ambidirectional cohort study, 1992-2024.BMC infectious diseases · 2026Article
- Survival outcomes and influencing factors in Zhengzhou HIV/AIDS patients following antiretroviral therapy initiation (2014-2024): a retrospective cohort analysis.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite expanded antiretroviral therapy (ART) coverage in China, AIDS remains a major public health challenge. This study aimed to assess survival outcomes and identify factors influencing survival time among HIV/AIDS patients receiving ART. Methods: This study was a retrospective cohort study utilizing data on HIV patients receiving antiretroviral therapy in Jiulongpo District, Chongqing, from 2012 to 2022. Life tables estimated cumulative survival, Kaplan-Meyer compared survival between groups, and accelerated time to failure (AFT) modeling was used for analysis of factors influencing survival time. Results: The 1-, 3-, 5-, and 10-year cumulative survival rates were 94% (95% CI: 0.93 to 0.95), 90% (95% CI: 0.89 to 0.91), 86% (95% CI: 0.85 to 0.87), and 79% (95% CI: 0.76 to 0.81), respectively. Compared to patients aged 15-29, those aged 30-49 (TR = 0.22, 95% CI: 0.11 to 0.46, Conclusion: Older age, males, lower educational attainment, homosexual contact, injection of drugs, and lower baseline CD4 levels are influential factors for shorter survival time in HIV/AIDS patients receiving ART. These findings may help inform clinical decision-making and targeted interventions to improve the long-term outcomes of people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.